On March 30, 2020, the parties reached a settlement agreement on behalf of a class of consumers and entities who purchased Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee.
As further detailed in Plaintiffs’ Unopposed Motion for Preliminary Approval, Celgene has agreed to pay $34 million to settle these claims.